Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

被引：0

作者：

Manier, Salomon ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Leleu, Xavier ^{[3
]}

Moreau, Philippe ^{[4
]}

Cavo, Michele ^{[5
]}

Goldschmidt, Hartmut ^{[6
]}

Orlowski, Robert Z. ^{[7
]}

Tron, Muriel ^{[8
]}

Tekle, Christina ^{[8
]}

Bregeault, Marie-France ^{[9
]}

Shafer, Andrea ^{[8
]}

Beksac, Meral ^{[10
]}

Facon, Thierry ^{[11
]}

机构：

[1] Univ Hosp Ctr Lille, Dept Hematol, Lille, France

[2] Univ Athens, Sch Med, Athens, Greece

[3] CHU Poitiers, Poitiers, France

[4] Univ Hosp Hotel Dieu, Hematol Dept, Paris, France

[5] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[6] Univ Hosp Heidelberg, Dept Internal Med 5, GMMG Study Grp, Heidelberg, Germany

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Sanofi, Baltimore, MD USA

[9] Sanofi, R&D, Vitry Sur Seine, France

[10] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye

[11] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-426

引用

页码：S290 / S291

页数：2

共 50 条

[1] Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis
An, Gang
Liu, Zhuogang
Jin, Jie
Cai, Zhen
Li, Wei
Xia, Zhongjun
Cen, Xinan
Hu, Yu
Mi, Jian-Qing
Jing, Hongmei
Zhan, Rong
Qu, Xiaoyan
Du, Xin
Gao, Dan
Zhao, Liang
Qiu, Lugui
BLOOD, 2024, 144 : 7055 - 7056
[2] Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
Orlowski, Robert Z.
Goldschmidt, Hartmut
Cavo, Michele
Martin, Thomas G.
Paux, Gautier
Oprea, Corina
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
Facon, Thierry
Dimopoulos, Meletios Athanasios
Leleu, Xavier P.
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir I.
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas G.
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert Z.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)
Facon, Thierry
Dimopoulos, Meletios
Leleu, Xavier
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S31 - S31
[5] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
LEUKEMIA, 2022, 36 (04) : 1066 - 1077
[6] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
Leukemia, 2022, 36 : 1066 - 1077
[7] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[8] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[9] Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Martinez-Lopez, Joaquin
Le Roux, Nadia
Mace, Sandrine
Rouchon, Marie-Claude
Wang, Qiuyan
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Leleu, Xavier P.
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Chretien, Marie-Lorraine
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →